

1FW

I hereby certify that this correspondence is being deposited with the United States Postal Service on the date set forth below as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Signature
And Deposit:

Dec 8, 2004

James C. Baker

Attorney of Record

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Howard J. Jacob, et al.
Serial No.: 10/625,870
Filed: July 23, 2003
For: RAT MODEL OF DIABETIC NEPHROPATHY
Group Art Unit: --
Examiner: --

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. 1.98, Applicants in the above-identified patent application wish to bring to the attention of the Examiner for consideration in connection with the examination on the merits of this patent application.

U.S. Patents

6,465,714; Luthman, et al.; October 15, 2002.

Other Documents

T. Abe, et al., "Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus Model Rats," Am. J. Physiol. Heart Circ. Physiol. 282(1):H138-148, 2002.

J. Chen, et al., "Endothelin Receptor Antagonist Combined with a Calcium Channel Blocker Attenuates Renal Injury in Spontaneous Hypertensive Rats with Diabetes," Chin. Med. J. (Engl.) 115(7):972-978, 2002.

J.T. Cheng, et al., "Stimulation of Insulin Release in Rats by Die-Huang-Wan, a Herbal Mixture used in Chinese Traditional Medicine," J. Pharm. Pharmacol. 53(2):273-276, 2001.

A.M. Cohen, et al., "The Cohen Diabetic (Non-Insulin-Dependent) Hypertensive Rat Model. Description of the Model and Pathologic Findings," Am. J. Hypertens. 6(12):989-995, 1993.

Y. Gu, et al., "The Effects of Endothelin Blockade on Renal Expression of Angiotensin II Type 1 Receptor in Diabetic Hypertensive Rats," Zhonghua Yi Xue Za Zhi 82(1):10-13, 2002.

S. Hoshi, et al., "Podocyte Injury Promotes Progressive Nephropathy in Zucker Diabetic Fatty Rats," Lab. Invest. 82(1):25-35, 2002.

N. Hosomi, et al., "Vascular Proliferation and Transforming Growth Factor-beta Expression in Pre- and Early Stage of Diabetes Mellitus in Otsuka Long-Evans Tokushima Fatty Rats," Atherosclerosis 162(1):69-76, 2002.

U. Janssen, et al., "Hypertension Superimposed on Type II diabetes in Goto Kakizaki Rats Induces Progressive Nephropathy," Kidney Int. 63(6):2162-2170, 2003.

S. Jesmin, et al., "Long-acting Calcium Channel Blocker Benidipine Suppresses Expression of Angiogenic Growth Factors and Prevents Cardiac Remodelling in a Type II Diabetic Rat Model," Diabetologia 45(3):402-415, 2002.

N. Kanemoto, et al., "Genetic Analysis of Pancreatic Duct Hyperplasia in Otsuka Long-Evans Tokushima Fatty Rats: Possible Association with a Region on Rat Chromosome 14 that includes the Disrupted Cholecystokinin-A Receptor Gene," Pathol. Int. 51(3):133-139, 2001.

P.J. Kaisaki, et al., "Localization, cDNA Sequence and Genomic Organization of the Rat Seipin Gene (Bsc12) and Sequence Analysis in Inbred Rat Models of Type 2 Diabetes Mellitus," Cytogenet. Genome Res. 98(1):71-74, 2002.

H. Masuda, "Effects of Temocapril on the Prevention of Early Diabetic Nephropathy in OLETF Rat, an Animal Model for Type 2 Diabetes," Hokkaido Igaku Zasshi 77(5):419-428, 2002.

S.A. Mifsud, et al., "Podocyte Foot Process Broadening in Experimental Diabetic Nephropathy: Amelioration with Renin-Angiotensin Blockade," Diabetologia 44(7):878-882, 2001.

M. de Aguiar Nobrega, "Distinct Genetic Regulation of the Onset and Progression of Diabetes and Renal Disease in the GOTO-Kakizaki (GK) Rat," pp. 1-275, April, 2001.

S.H. Park, et al., "Neointimal Hyperplasia After Arterial Injury is Increased in a Rat Model of Non-insulin-dependent Diabetes Mellitus," Circulation 104(7):815-819, 2001.

S.K. Park and S.K. Kang, "Renal Function and Hemodynamic Study in Obese Zucker Rats," Korean J. Intern. Med. 10(1):48-53, 1995.

C. Plachot, et al., "Impaired Beta-cell Regeneration After Partial Pancreatectomy in the Adult Goto-Kakizaki Rat, a Spontaneous Model of Type II Diabetes," Histochem. Cell Biol. 116(2):131-139, 2001.

P. Serradas, et al., "Fetal Insulin-like Growth Factor-2 Production is Impaired in the GK Rat Model of Type 2 Diabetes," Diabetes 51(2):392-397, 2002.

K. Sugimoto, et al., "Renal Protective Effect of YM598, a Selective Endothelin ET(A) Receptor Antagonist, against Diabetic Nephropathy in OLETF Rats," Eur. J. Pharmacol. 450(2):183-189, 2002.

Y. Sun, et al., "The Biomimetic [Cr(3)O(O(2)CCH(2)CH(3))(6)
(H(2)O)(3)](+) decreases Plasma Insulin, Cholesterol, and Triglycerides in
Healthy and Type II Diabetic Rats but not Type I Diabetic Rats," J. Biol. Inorg.
Chem. 7(7-8):852-862, 2002.

M.T. Velasque, et al., "Leptin and its Relation to Obesity and Insulin in the
SHR/N-corpulent Rat, a Model of Type II Diabetes Mellitus," Int. J. Exp. Diabetes
Res. 2(3):217-223, 2001.


S.N. Wang, et al., "Role of Glomerular Ultrafiltration of Growth Factors in
Progressive Interstitial Fibrosis in Diabetic Nephropathy," Kidney Int. 57(3):1002-
1014, 2000.

No fees are believed necessary to enter this statement. However, if any fees
are necessary please charge Deposit Account 17-0055.

Respectfully submitted,

Howard J. Jacob, et al.

December 8, 2004

By: 

Jean C. Baker
Reg. No. 35,433
Quarles & Brady LLP
411 East Wisconsin Avenue
Milwaukee, WI 53202-4497
(414) 277-5709

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/625,870	
			Filing Date	July 23, 2003	
			First Named Inventor	Howard J. Jacob	
			Group Art Unit		
			Examiner Name		
			Attorney Docket Number	650053.00002	
Sheet	1	of	3		

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



Please use a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete If Known			
		Application Number	10/625,870		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	July 23, 2003		
		First Named Inventor	Howard J. Jacob		
		Group Art Unit			
		Examiner Name			
Sheet	2	of	3	Attorney Docket Number	650053.00002


OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		T. Abe, et al., "Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus Model Rats," Am. J. Physiol. Hearst Circ. Physiol. 282(1):H138-148, 2002.	
		J. Chen, et al., "Endothelin Receptor Antagonist Combined with a Calcium Channel Blocker Attenuates Renal Injury in Spontaneous Hypertensive Rats with Diabetes," Chin. Med. J. (Engl.) 115(7):972-978, 2002.	
		J.T. Cheng, et al., "Stimulation of Insulin Release in Rats by Die-Huang-Wan, a Herbal Mixture used in Chinese Traditional Medicine," J. Pharm. Pharmacol. 53(2):273-276, 2001.	
		A.M. Cohen, et al., "the Cohen Diabetic (Non-Insulin-Dependent) Hypertensive Rat Model. Description of the Model and Pathologic Findings," Am. J. Hypertens. 6(12):989-995, 1993.	
		Y. Gu, et al., "The Effects of Endothelin Blockade on Renal Expression of Angiotensin II Type 1 Receptor in Diabetic Hypertensive Rats," Zhonghua Yi Xue Za Zhi 82(1):10-13, 2002.	
		S. Hoshi, et al., "Podocyte Injury Promotes Progressive Nephropathy in Zucker Diabetic Fatty Rats," Lab. Invest. 82(1):25-35, 2002.	
		N. Hosomi, et al., "Vascular Proliferation and Transforming Growth Factor-beta Expression in Pre- and Early Stage of Diabetes Mellitus in Otsuka Long-Evans Tokushima Fatty Rats," Atherosclerosis 162(1):69-76, 2002.	
		U. Janssen, et al., "Hypertension Superimposed on Type II Diabetes in Goto Kakizaki Rats Induces Progressive Nephropathy," Kidney Int. 63(6):2162-2170, 2003.	
		S. Jesmin, et al., "Long-acting Calcium Channel Blocker Benidipine Suppresses Expression of Angiogenic Growth Factors and Prevents Cardiac Remodelling in a Type II Diabetic Rat Model," Diabetologia 45(3):402-415, 2002.	
		N. Kanemoto, et al., "Genetic Analysis of Pancreatic Duct Hyperplasia in Otsuka Long-Evans Tokushima Fatty Rats: Possible Association with a Region on Rat Chromosome 14 that includes the Disrupted Cholecystokinin-A Receptor Gene," Pathol. Int. 51(3):133-139, 2001.	
		P.J. Kaisaki, et al., "Localization, cDNA Sequence and Genomic Organization of the Rat Seipin Gene (Bsc12) and Sequence Analysis in Inbred Rat Models of Type 2 Diabetes Mellitus," Cytogenet. Genome Res. 98(1):71-74, 2002.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type plus sign (+) inside the box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO		Complete if Known			
		Application Number	10/625,870		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	July 23, 2003		
		First Named Inventor	Howard J. Jacob		
		Group Art Unit			
		Examiner Name			
Sheet	3	of	3	Attorney Docket Number	650053.00002

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		H. Masuda, "Effects of Temocapril on the Prevention of Early Diabetic Nephropathy in OLETF Rat, an Animal Model for Type 2 Diabetes," Hokkaido Igaku Zasshi 77(5):419-428, 2002.	
		S.A. Mifsud, et al., "Podocyte Foot Process Broadening in Experimental Diabetic Nephropathy: Amelioration with Renin-Angiotensin Blockade," Diabetologia 44(7):878-882, 2001.	
		M. d Aguiar Nobrega, "Distinct Genetic Regulation of the Onset and Progression of Diabetes and Renal Disease in the GOTO-Kakizaki (GK) Rat," pp. 1-275, April, 2001.	
		S.H. Park, et al., "Neointimal Hyperplasia After Arterial Injury is Increased in a Rat Model of Non-insulin-dependent Diabetes Mellitus," Circulation 104(7):815-819, 2001.	
		S.K. Park and S.K. Kang, "Renal Function and Hemodynamic Study in Obese Zucker Rats," Korean J. Intern. Med. 10(1):48-53, 1995.	
		C. Plachot, et al., "Impaired Beta-cell Regeneration After Partial Pancreatectomy in the Adult Goto-Kakizaki Rat, a Spontaneous Model of Type II Diabetes," Histochem. Cell Biol. 116(2):131-139, 2001.	
		P. Serradas, et al., "Fetal Insulin-like Growth Factor-2 Production is Impaired in the GK Rat Model of Type 2 Diabetes," Diabetes 51(2):392-397, 2002.	
		K. Sugimoto, et al., "Renal Protective Effect of YM598, a Selective Endothelin ET(A) Receptor Antagonist, against Diabetic Nephropathy in OLETF Rats," Eur. J. Pharmacol. 450(2):183-189, 2002.	
		Y. Sun, et al., "the Biomimetic [Cr(3)O(O(2)CCH(2)CH(3))(6)(H(2)O)(3)](+) decreases Plasma Insulin, Cholesterol, and Triglycerides in Healthy and Type II Diabetic Rats but not Type I Diabetic Rats," J. Biol. Inorg. Chem. 7(7-8):852-862, 2002.	
		M.T. Velasque, et al., "Leptin and its Relation to Obesity and Insulin in the SHR/N-corpulent Rat, a Model of Type II Diabetes Mellitus," Int. J. Exp. Diabetes Res. 2(3):217-223, 2001.	
		S.N. Wang, et al., "Role of Glomerular Ultrafiltration of Growth Factors in Progressive Interstitial Fibrosis in Diabetic Nephropathy," Kidney Int. 57(3):1002-1014, 2000.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.